Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds

Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds

US Patent 10517861 · Granted Dec 31, 2019

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Biomarkers for a therapy comprising a sorafenib compound2025
Information processing apparatus and method and program for generating integrate2025
Pharmaceutical composition for treating tumor2024
Biomarkers for predicting and assessing responsiveness of thyroid and kidney can2023
Biomarkers for predicting and assessing responsiveness of thyroid and kidney can2023
Pharmaceutical composition for treating tumor2021
Combination of a PD-1 antagonist and eribulin for treating cancer2021
Biomarkers for predicting and assessing responsiveness of thyroid and kidney can2018
Biomarkers for predicting and assessing responsiveness of thyroid and kidney can2018
Antitumor agent using compounds having kinase inhibitory effect in combination2015
Notch-based fusion proteins and uses thereof2015
Therapeutic agent for tumor2015